Recent developments include leadership appointments, clinical trial progress, partnerships to streamline regulatory submissions, capital raises, and new data releases on cancer treatment mechanisms.

• Calidi Biotherapeutics appointed former Celgene executive Corsee Sander to its board of directors in June 2026 [N1].
• The company partnered with TransferAI to streamline IND submission for tumor virotherapy candidate CLD-401 in April 2026 [N2].
• Calidi released new data on its RedTail mechanism for cancer treatment in April 2026 [N3].
• In March 2026, Calidi closed a $6 million offering to advance its cancer immunotherapy pipeline [N4].
• The company reported a 23% reduction in net loss in fiscal Q2 2025 [N5].
• Calidi strengthened its leadership team with new CEO and Chief Medical Officer appointments in 2025 [N8].

Calidi has advanced its cancer immunotherapy pipeline through clinical trial progress, regulatory clearances, and strategic partnerships. The company has strengthened its leadership team with experienced executives and directors from the biotechnology sector. Recent capital raises provide funding to support ongoing development activities. The company's proprietary platforms and mechanisms, such as RedTail, represent potential innovative approaches in cancer treatment. These factors collectively support the company's operational visibility and development trajectory.

Calidi faces significant risks typical of clinical-stage biotechnology companies, including recurring operating losses, negative cash flows, and substantial accumulated deficits. Management has expressed substantial doubt about the company's ability to continue as a going concern without additional capital. The company's clinical candidates remain in early stages, with inherent uncertainties in clinical trial outcomes and regulatory approvals. Market risks include potential currency fluctuations due to international operations and the need for ongoing financing to sustain operations. These factors contribute to execution and financial risks for the company.

Calidi Biotherapeutics' moat is based on its proprietary cancer immunotherapy and antitumor virotherapy platforms, including its RedTail mechanism and clinical-stage candidates such as CLD-401 and CLD-201. The company's partnerships and regulatory progress, including FDA IND clearance and collaborations to streamline IND submissions, contribute to its competitive positioning. However, as a clinical-stage biotechnology company, its moat is contingent on successful clinical development and regulatory approvals, which remain uncertain and subject to typical industry risks.

• Going Concern and Financing Risk: The company has recurring losses and negative cash flows with substantial doubt about its ability to continue as a going concern without raising additional capital [S1].
• Clinical Development Risk: Calidi's pipeline candidates are in early clinical stages, and their success depends on clinical trial outcomes and regulatory approvals, which are uncertain [N2][S1].
• Market and Currency Risk: While currently not significantly exposed, future operations in Europe and Australia may expose the company to foreign currency exchange rate fluctuations [S1].
• Operational Execution Risk: Advancement of clinical trials, regulatory submissions, and partnerships require effective execution; delays or failures could impact the company's progress [N2][N4].

• Calidi Biotherapeutics, Inc. is a clinical-stage biotechnology company focused on cancer immunotherapy and antitumor virotherapy platforms [S1].
• The company operates through wholly-owned subsidiaries including StemVac GmbH in Germany and Calidi Biotherapeutics Australia Pty Ltd for clinical trial activities in Australia [S1].
• Calidi's leadership includes CEO Eric Poma (appointed April 2025), CFO Andrew Jackson (since October 2023), and Chief Scientific Officer Antonio F. Santidrian (since July 2023) [S1].
• The company has a board of directors with members experienced in biotechnology and healthcare sectors [S1].
• Calidi's clinical pipeline includes tumor virotherapy candidate CLD-401 and solid tumor treatment candidate CLD-201, with FDA IND clearance for CLD-201 and ongoing clinical trials for CLD-101 targeting recurrent glioma [N2][S1].
• Recent partnerships include collaboration with TransferAI to streamline IND submission for CLD-401 and with Avance Clinical for trial initiation in Australia [N2][N4].
• Calidi released new data on its RedTail mechanism for cancer treatment in April 2026 [N3].
• The company closed a $6 million offering in March 2026 to advance its cancer immunotherapy pipeline [N4].
• Financial snapshot as of June 30, 2026: cash and equivalents of $9.6 million (as of Dec 31, 2024 $9.6M), current assets $5.43 million, current liabilities $3.24 million, current ratio 1.68, cash ratio 2.97 [S2].
• Net loss for the six months ended June 30, 2026 was $4.16 million with basic and diluted EPS of -$2.94 per share [S2].
• The company has experienced recurring losses and negative cash flows from operations, with an accumulated deficit of $141.6 million as of December 31, 2025 [S1].
• Management has expressed substantial doubt about the company's ability to continue as a going concern within 12 months from the 2025 10-K issuance date, dependent on raising additional capital [S1].
• Calidi has taken steps to strengthen its leadership team and advance its antitumor virotherapy platform, including CEO and Chief Medical Officer appointments in 2025 [N8].
• The company has conducted clinical trial updates and recruitment for its CLD-101 trial targeting high-grade glioma [N8].
• Calidi has engaged in public offerings and warrant exercises to raise capital, including a $5.2 million public offering in March 2026 and warrant exercises anticipating $4.6 million in proceeds in 2025 [N7][N4].
• The company is classified as an emerging growth company and smaller reporting company, with reduced reporting requirements under the JOBS Act [S1].
• Calidi is not currently exposed to significant market risk from interest rate or foreign currency fluctuations but operates subsidiaries in Europe and Australia which may expose it to currency risk in the future [S1].
• The company’s disclosure controls and procedures were evaluated as effective as of December 31, 2025 [S1].